Medicines Discovery Catapult has agreed with Alderley Park Ltd to integrate Alderley Park’s imaging services and expertise into their pre-clinical imaging capability, further enhancing their offering to UK SMEs.
Medicines Discovery Catapult will now offer collaborative research programmes across a range of advanced preclinical imaging and bioanalysis technologies that will drive future drug discovery and development across the UK.
The new imaging capabilities integrated into Medicines Discovery Catapult from Alderley Park includes the Siemens Inveon Positron Emission Tomography and Computed Tomography Scanners, PE Wallac Wizard gamma Counter, and VisualSonics Fujifilm High Frequency ultrasound imaging system.
These services will now be combined with Medicines Discovery Catapult’s wider suite of technologies for preclinical drug discovery. These include:
- Waters Desorption Electro Spray Ionisation – Mass Spectrometry
- Rapid Evaporative Ionisation and Acoustic Mist Ionisation – Mass Spectrometry
- Perkin Elmer IVIS Lumina III near infra-red imaging.
The unique combination of preclinical imaging capabilities and expertise, alongside mass spectrometry, biomarker profiling, molecular pathology and super-resolution imaging, provides deeply informative data sets for better project decision-making.
Chris Molloy, Chief Executive Officer of Medicines Discovery Catapult, said: “We work at the forefront of drug discovery technology innovation, so that UK SMEs can access scarce, state-of-the-art technologies and expertise that enable their projects.
“The incorporation of Alderley Park’s imaging capabilities enhances our portfolio, with the ability to prove that these techniques are on the critical path for the future of medicines R&D.”
Dr Chris Doherty, Managing Director, of Alderley Park Limited said:
“The imaging service we had complements the imaging service the Catapult already provides and there’s more value to be had by putting the two services together.”